Basel, Switzerland – 20 Sept 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today it is a proud sponsor of the 5^th Vasculitis Training Course organized by the European Vasculitis Society (EUVAS) being held 28-30 September in St Gallen, Switzerland.

“We are pleased to have Alentis as one of the sponsors for the EUVAS Vasculitis Training Course”, said Dr. David Jayne, co-founder and the current President of EUVAS. “With the training course we aim to provide medical education on vasculitis to physicians, researchers and others interested in vasculitis.”

Dr. Luigi Manenti, Chief Medical Officer of Alentis said, “We are honored to support this important event for medical experts in vasculitis. We are committed to develop our investigational therapy ALE.F02 as a potential treatment for ANCA-associated vasculitis with renal involvement to address the huge unmet medical need for these patients.”

About ALE.F02
ALE.F02 is a first-in-class monoclonal antibody developed to specifically target a unique CLDN1 epitope exposed in fibrotic in order to reverse the disease. ALE.F02 is an investigational antibody that was observed to be well tolerated, with no serious safety concerns, during Phase 1 single- and multiple-ascending dose studies in healthy volunteers.

About EUVAS
The European Vasculitis Society (EUVAS) is a nonprofit organization committed to uniting vasculitis researchers and clinicians promoting the study and the treatment of vasculitis. The open collaboration of physicians has representatives from many medical specialties based both inside and outside the European Union. EUVAS conducts clinical trials and studies into the assessment of vasculitis and partners with interested researchers in the development of collaborative studies and offers organizational support through its office.

About Alentis Therapeutics
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is the leading company pioneering a novel approach to modify and reverse the course of disease by targeting CLDN1, a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease.

Alentis was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in pharma-biotech hub Basel, Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US. Visit https://alentis.ch